DUPIXENT® clinical trials in CRSwNP (N=724)

SINUS-24 and SINUS-52 were randomized, double-blind, parallel-group, multicenter, placebo-controlled studies in 724 patients aged 18 years and older on background intranasal corticosteroids (INCS)

 

 

SINUS-24 (N=276) 24 WEEKS

SINUS-52 (N=448) 52 WEEKS

Randomized

DUPIXENT® + INCS

300 mg Q2W for 24 weeks (n=143)

Placebo + INCS for 24 weeks (n=133)

DUPIXENT® + INCS

300 mg Q2W for 52 weeks (n=150)a

DUPIXENT® + INCS

300 mg Q2W for 24 weeks, followed by Q4W
through week 52 (n=145)b

Placebo + INCS for 52 weeks (n=153)

Study population

Adults (aged ≥18 years) on background INCS with CRSwNP despite prior sino-nasal surgery or prior treatment with, or who were ineligible to receive or were intolerant to, systemic steroids in the past 2 yearsc
Patients with chronic rhinosinusitis without nasal polyposis were not included in these trials
 Rescue with systemic steroids or surgery was allowed at investigators’ discretion

Adapted from the Product Monograph.


a In SINUS-52, data from baseline to week 24 are pooled DUPIXENT® Q2W treatment arms (n=295).
b The recommended dose of DUPIXENT® for adult patients with CRSwNP is 300 mg given subcutaneously every other week.
c All patients in the placebo and DUPIXENT® arms were on a background therapy of INCS.

Connect With a Rep

Have questions about DUPIXENT®? Get answers from a representative.

Freedom support program logo.

Freedom Support Program

Find out what the Freedom Support Program can bring to your patients and how you can help them access it.



DUPIXENT®, Sanofi and Freedom logos are trademarks of Sanofi, used under license by sanofi-aventis Canada Inc.
REGENERON® is a trademark of Regeneron Pharmaceuticals, Inc. All rights reserved.
© 2023 sanofi-aventis Canada Inc. All rights reserved.

MAT-CA-2300229E
Last updated: 06/2023

paab logo